Addendum
Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) – Addendum to Commission A21-145
Report documents
-
Addendum
Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) – Addendum to Commission A21-145
Dossier assessment
Adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumours express PD-L1 (combined positive score ≥ 10) and who have not received prior chemotherapy for metastatic disease
Unchanged after addendum: Hint of non-quantifiable added benefit
Additional information
Federal Joint Committee (G-BA)
2022-05-05 A G-BA decision was published.
Project details
- Project no.
- A22-36
- Commission
- Commission awarded on 30.03.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (endometrial carcinoma) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (cervical cancer, combination with chemoradiotherapy) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (NSCLC, adjuvant) – Benefit assessment according to § 35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (cervical cancer) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (renal cell carcinoma) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (bile cancer) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (small bowel cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (gastric cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (endometrial cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (colorectal cancer) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (melanoma, advanced) – Benefit assessment according to § 35a SGB V
Status: Commission completed
-
Dossier assessment
Pembrolizumab (melanoma, adjuvant) – Benefit assessment according to § 35a SGB V
Status: Commission completed